Banco Santander S.A. lifted its position in PerkinElmer, Inc. (NYSE:PKI – Get Rating) by 13.1% in the 1st quarter, HoldingsChannel.com reports. The firm owned 39,402 shares of the medical research company’s stock after acquiring an additional 4,570 shares during the quarter. Banco Santander S.A.’s holdings in PerkinElmer were worth $6,874,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors also recently added to or reduced their stakes in PKI. Janney Montgomery Scott LLC grew its holdings in shares of PerkinElmer by 14.2% in the fourth quarter. Janney Montgomery Scott LLC now owns 3,875 shares of the medical research company’s stock valued at $779,000 after purchasing an additional 483 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in PerkinElmer during the fourth quarter worth about $3,530,000. D.A. Davidson & CO. boosted its stake in PerkinElmer by 15.4% during the fourth quarter. D.A. Davidson & CO. now owns 1,502 shares of the medical research company’s stock worth $302,000 after buying an additional 200 shares during the period. CWM LLC purchased a new position in PerkinElmer during the fourth quarter worth about $196,000. Finally, Xponance Inc. boosted its stake in PerkinElmer by 38.0% during the fourth quarter. Xponance Inc. now owns 8,009 shares of the medical research company’s stock worth $1,610,000 after buying an additional 2,205 shares during the period. 89.27% of the stock is currently owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other news, insider Daniel R. Tereau sold 5,700 shares of the firm’s stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $145.14, for a total transaction of $827,298.00. Following the transaction, the insider now directly owns 13,380 shares in the company, valued at $1,941,973.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Daniel R. Tereau sold 5,700 shares of PerkinElmer stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $145.14, for a total value of $827,298.00. Following the transaction, the insider now directly owns 13,380 shares in the company, valued at approximately $1,941,973.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Andrew Okun sold 3,173 shares of PerkinElmer stock in a transaction on Monday, August 1st. The shares were sold at an average price of $165.42, for a total transaction of $524,877.66. Following the completion of the transaction, the insider now owns 6,391 shares in the company, valued at $1,057,199.22. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,898 shares of company stock valued at $2,083,263. 0.52% of the stock is owned by corporate insiders.
PerkinElmer Stock Up 0.5 %
PerkinElmer (NYSE:PKI – Get Rating) last released its quarterly earnings data on Monday, August 1st. The medical research company reported $2.32 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.31. PerkinElmer had a net margin of 13.21% and a return on equity of 16.68%. The company had revenue of $1.23 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter last year, the company earned $2.83 earnings per share. The firm’s revenue for the quarter was up .1% on a year-over-year basis. As a group, equities research analysts predict that PerkinElmer, Inc. will post 7.83 earnings per share for the current fiscal year.
PerkinElmer Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 11th. Shareholders of record on Friday, October 21st will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, October 20th. This represents a $0.28 dividend on an annualized basis and a yield of 0.18%. PerkinElmer’s payout ratio is currently 5.24%.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the stock. Robert W. Baird increased their target price on shares of PerkinElmer from $198.00 to $202.00 and gave the stock an “outperform” rating in a research note on Tuesday. Barclays increased their price target on shares of PerkinElmer from $125.00 to $149.00 and gave the stock an “underweight” rating in a research report on Tuesday. UBS Group began coverage on shares of PerkinElmer in a research report on Wednesday, July 20th. They set a “buy” rating and a $160.00 price target on the stock. The Goldman Sachs Group reduced their price target on shares of PerkinElmer from $200.00 to $175.00 and set a “neutral” rating on the stock in a research report on Thursday, July 14th. Finally, Citigroup reduced their price target on shares of PerkinElmer from $185.00 to $170.00 in a research report on Wednesday, May 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $161.13.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
- Get a free copy of the StockNews.com research report on PerkinElmer (PKI)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.